High dose AZQ in renal cancer. A Southwest Oncology Group phase II study.
Fifty-seven patients with renal cancer were treated with AZQ, utilizing one of three IV push schedules. Only one partial response was seen in 55 evaluable patients, and considerable myelosuppression was encountered. Gastrointestinal toxicity was more severe in those patients who had received prior treatment. At these higher doses AZQ is deemed an inactive agent in patients with renal cell carcinoma, at least when the drug is administered as a push schedule.
R L
RL
Stephens
R
R
Kirby
E D
ED
Crawford
R
R
Bukowski
S E
SE
Rivkin
R M
RM
O'Bryan
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001388:Aziridines / Q000009:adverse effects / Q000627:therapeutic use*; D001389:Azirines / Q000627:therapeutic use*; D016227:Benzoquinones; D001855:Bone Marrow Diseases / Q000139:chemically induced; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D004341:Drug Evaluation; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D007958:Leukocyte Count; D010976:Platelet Count
D000970:Antineoplastic Agents; D001388:Aziridines; D001389:Azirines; D016227:Benzoquinones; C029108:diaziquone